Cartesian Therapeutics

Yahoo Finance • 10 days ago

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of induce... Full story

Yahoo Finance • 22 days ago

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients. MG... Full story

Yahoo Finance • last month

Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating

Investing.com - Wedbush initiated coverage on Cartesian Therapeutics (NASDAQ:RNAC) with an Outperform rating and a price target of $38.00 on Wednesday. According to InvestingPro data, analysts maintain a strong buy consensus with price tar... Full story

Yahoo Finance • 3 months ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the... Full story

Yahoo Finance • 4 months ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its manag... Full story

Yahoo Finance • 5 months ago

Cartesian Therapeutics Announces New Employment Inducement Grant

FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announc... Full story

Yahoo Finance • 6 months ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its manage... Full story

Yahoo Finance • 7 months ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has recei... Full story

Yahoo Finance • last year

Insiders Are Buying These 11 Penny Stocks

In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock market started the second quarter of 2024... Full story